NASDAQ · ATEC

Alphatec Holdings, Inc.

Healthcare · Medical - Devices

$10.39▲ 2.16% ($0.22)today

As of 3:39 PM ET

52-week

$6.82$23.29

Market cap

$1.60B

P/E

What the market price implies · Reverse DCF

Historical revenue grew by 33.14%/yr over the past 4 years.

Selected forecast · Base scenario

15.92%/yr · actual 10-year annualized revenue growth

Year 1 growth: 25.01%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$10.39

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Year 1 growth 25.01% · Ending margin 0% · Discount rate 8.57%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 7:39 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 22, 2026, 7:39 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -33.37%Revenue (TTM): 19.47%FCF (TTM): 113.83%P/S: 34th pct

What changed

The stock fell 33.37% over the last year. Revenue grew 19.47% over the trailing twelve months. Operating margin moved from -16.84% to -5.55%. Free cash flow grew 113.83% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read changes if operating margin (currently -5.55%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions.

CEOPatrick S. Miles

SectorHealthcare

IndustryMedical - Devices

Employees913

IPO dateJun 1, 2006

https://www.atecspine.com

Market multiples

Forward P/E—

EV/EBITDA-91.10

Enterprise value$3.62B

Stock splits

Aug 25, 2016↓ Reverse

Every 12 shares became 1

-92%

Profitability & growth

Revenue growth15.07%

Gross margin (FY2025)69.6%▲0.2ppvs FY2024

Operating margin (FY2025)-10.75%▲11.5ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$16.22▲56.11%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Oct 29, 2026

Q4 FY26 · EPS est $0.11 · Revenue est $225.44M

View